TOP TEN perturbations for 39714_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39714_at
Selected probe(set): 201312_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39714_at (201312_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Relative Expression (log2-ratio):7.6104755Number of Samples:4 / 2
| Experimental | lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):-6.6049805Number of Samples:2 / 3
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |
MCF-7:2A / MCF-7
Relative Expression (log2-ratio):5.8968725Number of Samples:4 / 4
| Experimental | MCF-7:2A |
| Long-term estrogen deprived breast cancer cells MCF-7, which are resistant to estrogen-deprivation and therefore show an aromatase inhibitor resistantance. MCF-7 is human metastatic cancer cell line derived from the pleural effusion of a patient with adenocarcinoma of the breast. Parental cell line:: MCF-7 Cellosaurus code: | |
| Control | MCF-7 |
| Human metastatic cancer cell line derived from the pleural effusion of a patient (69 years old, caucasian) with adenocarcinoma of the breast. Synonyms:MCF 7; MCF.7; MCF7; Michigan Cancer Foundation 7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL Cellosaurus code: |
lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Relative Expression (log2-ratio):5.750392Number of Samples:43 / 2
| Experimental | lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). |
MCF-7.5C / MCF-7
Relative Expression (log2-ratio):5.7260704Number of Samples:3 / 4
| Experimental | MCF-7.5C |
| Human metastatic cancer cell line derived from the pleural effusion of a patient with adenocarcinoma of the breast. Long-term estrogen deprived breast cancer cells, which are resistant to estrogen-deprivation and therefore show an aromatase inhibitor resistantance. Parental cell line:: MCF-7 Synonyms:MCF-7 clone 5C; 5C; MCF-7:5C Cellosaurus code: | |
| Control | MCF-7 |
| Human metastatic cancer cell line derived from the pleural effusion of a patient (69 years old, caucasian) with adenocarcinoma of the breast. Synonyms:MCF 7; MCF.7; MCF7; Michigan Cancer Foundation 7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL Cellosaurus code: |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Relative Expression (log2-ratio):-5.5242395Number of Samples:2 / 4
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; adenosquamous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-4.9196596Number of Samples:2 / 22
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the lung (subcutaneously implanted). |
IGF-I study 1 (4h; 5nM; T47D-YA/IRS-1 C20) / IGF-I study 1 (4h; 5nM; T47D-YA/IRS-1 C10)
Relative Expression (log2-ratio):-4.905222Number of Samples:3 / 3
| Experimental | IGF-I study 1 (4h; 5nM; T47D-YA/IRS-1 C20) |
| Human breast cancer cell line T47D-YA/IRS-1 C20 samples collected 4 hours after treatment with 5 nM IGF-I (insulin-like growth factor I). The cell line was maintained in MEM, 5% fetal bovine serum, penicillin/streptomycin, 1X non-essential amino acids, 6 ng/l insulin, 50 ug/ml G418, and 100 ug/ml hygromycin B. Cells were plated at a density of 3x10exp6 in 150 mm dishes overnight, then the media were replaced by SFM (serum-free media) alone for 24 h prior the treatment. After 24 hours, the cells were treated with SFM plus fibronectin (2 ug/ml) and IGF-I for 4 hours. | |
| Control | IGF-I study 1 (4h; 5nM; T47D-YA/IRS-1 C10) |
| Human breast cancer cell line T47D-YA/IRS-1 C10 samples collected 4 hours after treatment with 5 nM IGF-I (insulin-like growth factor I). The cell line was maintained in MEM, 5% fetal bovine serum, penicillin/streptomycin, 1x non-essential amino acids, 6 ng/l insulin, 50 ug/ml G418, and 100 ug/ml hygromycin B. Cells were plated at a density of 3x10exp6 in 150 mm dishes overnight, then the media were replaced by SFM (serum-free media) alone for 24 h prior the treatment. After 24 hours, the cells were treated with SFM plus fibronectin (2 ug/ml) and IGF-I for 4 hours. |
RAF1 overexpr. study 1 (retrovirus) / control virus infected MCF7 cell sample
Relative Expression (log2-ratio):-4.8088675Number of Samples:2 / 2
| Experimental | RAF1 overexpr. study 1 (retrovirus) |
| MCF-7 cell line stably transfected with retrovirus containing cDNA for RAF1. The following retroviral construct was used: pLNCRaf-1 contains human Raf-1 cDNA encoding an amino terminally truncated form of Raf-1 that is constitutively active, which is inserted into retroviral vector pLNCX encoding neomycin resistance gene (NeoR). MCF7 cells were maintained in EMEM supplemented with 10% FBS and 20ug/ml insulin. | |
| Control | control virus infected MCF7 cell sample |
| MCF7 cell line transfected with pZipneo retrovirus, which is an empty retroviral vector encoding neomycine resistance gene (NeoR). MCF7 cells were maintained in EMEM supplemented with 10% FBS and 20ug/ml insulin. |
IGF-I study 1 (24h; 5nM; T47D-YA/IRS-1 C20) / IGF-I study 1 (24h; 5nM; T47D-YA/IRS-1 C10)
Relative Expression (log2-ratio):-4.6236053Number of Samples:3 / 3
| Experimental | IGF-I study 1 (24h; 5nM; T47D-YA/IRS-1 C20) |
| Human breast cancer cell line T47D-YA/IRS-1 C20 samples collected 24 hours after treatment with 5 nM IGF-I (insulin-like growth factor I). The cell line was maintained in MEM, 5% fetal bovine serum, penicillin/streptomycin, 1X non-essential amino acids, 6 ng/l insulin, 50 ug/ml G418, and 100 ug/ml hygromycin B. Cells were plated at a density of 3x10exp6 in 150 mm dishes overnight, then the media were replaced by SFM (serum-free media) alone for 24 h prior the treatment. After 24 hours, the cells were treated with SFM plus fibronectin (2 ug/ml) and IGF-I for 24 hours. | |
| Control | IGF-I study 1 (24h; 5nM; T47D-YA/IRS-1 C10) |
| Human breast cancer cell line T47D-YA/IRS-1 C10 samples collected 24 hours after treatment with 5 nM IGF-I (insulin-like growth factor I). The cell line was maintained in MEM, 5% fetal bovine serum, penicillin/streptomycin, 1X non-essential amino acids, 6 ng/l insulin, 50 ug/ml G418, and 100 ug/ml hygromycin B. Cells were plated at a density of 3x10exp6 in 150 mm dishes overnight, then the media were replaced by SFM (serum-free media) alone for 24 h prior the treatment. After 24 hours, the cells were treated with SFM plus fibronectin (2 ug/ml) and IGF-I for 24 hours. |